Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 9, 2019July 9, 2019

Zogenix Resubmitting New Drug Application to FDA for Fintepla Anti-Seizure Therapy

News

Zogenix has announced it will resubmit a New Drug Application (NDA) for Fintepla (ZX008), its investigational anti-seizure therapy for patients with Dravet syndrome, likely in the third quarter of this ... Read more

July 2, 2019July 2, 2019

Epygenix Submits Investigational New Drug Application for Dravet Therapy

News

Epygenix Therapeutics has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to assess the safety and efficacy of EPX-100, its investigational ... Read more

March 26, 2019March 26, 2019

Nippon Shinyaku to Market Fintepla in Japan for Treatment of Dravet Syndrome Seizures

News

Zogenix‘s investigational therapy Fintepla (ZX008) to treat epileptic seizures associated with Dravet syndrome will be marketed in Japan by pharmaceutical company Nippon Shinyaku. Fintepla is a low-dose oral solution of fenfluramine ... Read more

October 4, 2018October 4, 2018

FDA Approves Fycompa for Treatment of Focal Seizures in Children Ages 4 and Older

News

The U.S. Food and Drug Administration has approved Fycompa (perampanel) — alone or as an add-on — for the treatment of focal seizures, which affect only one part of the ... Read more

November 7, 2018November 7, 2018

Epidiolex Now Available in the U.S. for Lennox-Gastaut and Dravet Patients 2 and Older

News

Epidiolex (cannabidiol) oral solution is now available in the United States as a treatment for seizures in patients age 2 or older who have Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex is developed ... Read more

November 1, 2018November 1, 2018

Stiripentol Reduces Seizure and Resolves Status Epilepticus, Small Study Reports

News

Treatment with stiripentol reduces seizures and can resolve epileptic episodes, retrospective analysis of a small study in Turkish Dravet syndrome children suggests. The study, “Efficacy of Stiripentol and the Clinical Outcome ... Read more

October 16, 2018October 16, 2018

Fenfluramine May Help Reduce Seizures in Dravet Syndrome, Review Study Reports

News

Fenfluramine, originally developed as an appetite suppressant, shows potential as an anti-epileptic therapy to reduce the seizure rate in Dravet syndrome patients, a review study suggests. The study, “Individualized ... Read more

September 25, 2018September 25, 2018

Supernus Acquires Biscayne, Takes Over BIS-001ER Clinical Program for Dravet Syndrome

News

Supernus Pharmaceuticals now holds the worldwide rights — except in certain markets in Asia — to develop the investigational therapy BIS-001ER, renamed SPN-817, for Dravet syndrome, after a merger ... Read more

August 23, 2018August 23, 2018

FDA Approves Diacomit as Add-On Therapy for Dravet Syndrome

News

The U.S. Food and Drug Administration (FDA) has approved Biocodex’s Diacomit (stiripentol) as an add-on therapy for seizures associated with Dravet syndrome in patients 2 years and older who are undergoing treatment with ... Read more

August 17, 2018August 19, 2018

Dravet Study Links Early Use of Sodium Channel Blockers, Worse Cognitive Function

Just Published, News

Long-term use of sodium channel blockers in the first five years of disease has been linked to poorer cognitive function in Dravet syndrome patients. The study, “Influence of contraindicated ... Read more

Pin It on Pinterest